Samrat Pharmachem Ltd-$
Samrat Pharmachem Ltd-$ (SAMRATPH) last traded at ₹245, a market capitalisation of ₹75.6 crore. Over the past 52 weeks the stock has ranged between ₹190 and ₹333. Samrat Pharmachem Ltd-$ last reported results for the quarter ended Jun 2026, with sales of ₹79.76 crore and net profit of ₹0.88 crore. Figures are as of 25 Aug 2026 and are not real time.
Samrat Pharmachem Ltd-$ share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Samrat Pharmachem Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹79.76 cr, up 5.4% from ₹75.65 cr a year earlier. Net profit turned positive at ₹0.88 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 70.17 | 63.66 | 71.2 | 75.65 | 78.87 | 63.43 | 71.77 | 79.76 |
| Expenses | 66.8 | 59.48 | 71.07 | 75.52 | 79.23 | 64.08 | 73.01 | 78.87 |
| Operating profit | 3.37 | 4.18 | 0.13 | 0.13 | -0.36 | -0.65 | -1.24 | 0.89 |
| OPM % | 4.80% | 6.57% | 0.18% | 0.17% | -0.46% | -1.02% | -1.73% | 1.12% |
| Other income | 0.49 | 0 | -0.11 | 0.69 | 0.05 | 0.4 | -0.31 | 0.99 |
| Interest | 0.17 | 0.1 | 0.22 | 0.44 | 0.26 | 0.13 | 0.14 | 0.11 |
| Depreciation | 0.17 | 0.17 | 0.16 | 0.17 | 0.18 | 0.19 | 0.19 | 0.19 |
| Profit before tax | 3.52 | 3.91 | -0.36 | 0.21 | -0.75 | -0.57 | -1.88 | 1.58 |
| Tax % | 24.43% | 28.90% | 11.11% | 209.52% | -21.33% | -19.30% | 8.51% | 44.94% |
| Net profit | 2.66 | 2.78 | -0.4 | -0.23 | -0.59 | -0.46 | -2.04 | 0.88 |
| EPS (₹) | 8.61 | 9.00 | -1.29 | -0.74 | -1.91 | -1.49 | -6.60 | 2.85 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Samrat Pharmachem Ltd-$ annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 179 | 222 | 311 | 282 | 286 | 290 | 294 |
| Operating profit | 9 | 24 | 24 | 2 | 10 | -2 | -1 |
| OPM % | 4.8% | 11% | 8% | 0.9% | 3.6% | -0.7% | -0.5% |
| Net profit | 5 | 17 | 17 | 2 | 7 | -3 | -2 |
| EPS (₹) | 17.25 | 55.60 | 53.82 | 6.99 | 23.01 | -10.71 | -7.15 |
TTM is the trailing twelve months to the most recent quarter.
Samrat Pharmachem Ltd-$ growth and returns
- 10 Years
- 16%
- 5 Years
- 10%
- 3 Years
- -2%
- TTM
- 5%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -146%
- 10 Years
- 22%
- 5 Years
- 4%
- 3 Years
- -16%
- 1 Year
- -23%
- 10 Years
- 14%
- 5 Years
- 13%
- 3 Years
- 2%
- Last Year
- -5%
Samrat Pharmachem Ltd-$ shareholding pattern
Promoters held 49.09% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.24% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.95% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% |
| FIIs | 3.24% | 3.24% | 3.24% | 0.00% | 3.24% | 3.24% | 3.24% | 3.24% |
| DIIs | 0.00% | 0.00% | 0.00% | 3.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 47.81% | 47.66% | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% | 47.66% |
| No. of shareholders | 6,984 | 6,844 | 6,785 | 6,752 | 6,699 | 6,488 | 6,311 | 6,330 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Samrat Pharmachem Ltd-$ corporate filings
- Newspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended June 30, 2026.Company Updatemedium impact
Cruxal's analysis: Samrat Pharmachem Limited has declared its standalone unaudited financial results for the…
Read the full analysis - The Board considered and adopted the unaudited financial results for the quarter ended June 30, 2026Board Meetinghigh impact
Cruxal's analysis: Samrat Pharmachem Limited has reported a significant financial turnaround for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Samrat Pharmachem Ltd-$
Cruxal reads every Samrat Pharmachem Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.